The lncRNA RP11-142A22.4 promotes adipogenesis by sponging miR-587 to modulate Wnt5β expression

Tongtong Zhang¹, Hongtao Liu², Rui Mao², Huawu Yang³, Yuanchuan Zhang³, Yu Zhang², Pengsen Guo², Dafang Zhan³, Bin Xiang⁴ and Yanjun Liu³

Abstract
Emerging evidence suggests that long noncoding RNAs (lncRNAs) play essential roles in the regulation of gene expression. However, the functional contributions of lncRNAs to adipogenesis remain largely unexplored. In this study, we investigated global changes in the expression patterns of lncRNAs in visceral adipose tissue and identified RP11-142A22.4 as a significantly upregulated lncRNA. In isolated preadipocytes, knockdown of RP11-142A22.4 inhibited differentiation and reduced C/EBP-α and PPAR-γ expression. Investigations of the underlying mechanisms revealed that RP11-142A22.4 contains a functional miR-587 binding site. Mutation of the binding sites for RP11-142A22.4 in miR-587 abolished the interaction, as indicated by a luciferase reporter assay. Furthermore, RP11-142A22.4 affected the expression of miR-587 and its target gene Wnt5β. Overexpression of miR-587 blocked the inhibitory effect of RP11-142A22.4 on preadipocyte differentiation. Moreover, the downregulation of miR-587 restored preadipocyte differentiation upon inhibition by RP11-142A22.4 silencing. Our results suggest that RP11-142A22.4 can control adipocyte differentiation via the miR-587/Wnt5β signaling pathway and serve as a potential target for obesity treatments.

Introduction
Obesity has emerged as an epidemic and has become an unprecedented public health challenge. Previous studies have suggested that an increase in adipose tissue is the main cause of obesity and the associated complications. Therefore, to understand the functional mechanisms of obesity, it is necessary to study the adipose tissue of obese people.

Over the past years, many crucial obesity-associated genes have been discovered, but their exact functional mechanisms have not yet been fully clarified. Noncoding RNAs (ncRNAs), a group of transcripts showing no protein-coding capacity, have been found to participate in multiple biological and physiological processes. Long noncoding RNAs (lncRNAs) are described as highly conserved ncRNAs with a length of more than 200 nucleotides. Several studies have indicated that lncRNAs play a key role in the occurrence and development of obesity and have been considered important regulators of obesity. Despite these findings, the regulatory mechanisms of lncRNAs in adipogenesis are far from understood.

In the present study, we profiled the lncRNA expression patterns in visceral adipose tissue (VAT) of lean people and obese people and found that lncRNA RP11-142A22.4 is the most highly upregulated lncRNA in obese people compared with lean people. Furthermore, we found that RP11-142A22.4 binds to miR-587 to upregulate Wnt5β expression.
expression. Together, our results imply that RP11-142A22.4 plays a crucial role in adipogenesis and could serve as a potential therapeutic target for obesity treatment.

**Materials and methods**

**Clinical data**

VAT samples were collected from 60 patients undergoing laparoscopic hernia repair (in lean [Ln] volunteers) and 40 patients undergoing bariatric surgery (in obese [Ob] subjects) at the Third People’s Hospital of Chengdu, Chengdu, China, between December 2016 and November 2017 (Table S1). This study was approved by the Institutional Ethics Review Board of the Third People’s Hospital of Chengdu (record #: 2018S75; Chengdu, Sichuan, China) and was conducted in accordance with the Chinese ethical guidelines for human genome/gene research.

**LncRNA microarray expression profiling**

Total RNA was extracted with TRIzol reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s instructions. RNA integrity was assessed by an Agilent Bioanalyzer 2100 (Agilent Technologies, Santa Clara, CA, USA). Qualified total RNA was further purified by the RNeasy Mini Kit (Qiagen, GmBH, Germany) and RNase-Free DNase Set (Qiagen, GmBH, Germany). Probe synthesis and hybridization to Agilent Human 180K LncRNA Microarray v4.0 (Agilent, Santa Clara, CA, USA) were performed by a Gene Expression Hybridization Kit (Agilent, Santa Clara, CA, USA) in a hybridization oven (Agilent, Santa Clara, CA, USA) according to the manufacturer’s instructions. The images were scanned by an Agilent scanner (Agilent, Santa Clara, CA, USA), and the raw data were normalized by a quantile algorithm (GeneSpring Software 11.0, Agilent, Santa Clara, CA, USA). For differentially expressed lncRNAs, we calculated the fold change and the P-value (with Student’s t test). The threshold for up- and downregulated genes was fold change >2.0 and a P-value <0.05. Hierarchical clustering was performed to display the difference in gene expression patterns between the two samples. The obtained lncRNA microarray datasets were deposited into the NCBI Gene Expression Omnibus (GEO) repository under accession number GSE131819.

**Real-time quantitative reverse transcription-polymerase chain reaction**

Total RNA was reverse-transcribed into cDNA with random primers using the Transcriptor First Strand cDNA Synthesis Kit (Roche, Penzberg, Germany) following the manufacturer’s instructions. RP11-142A22.4 expression was measured by real-time quantitative reverse transcription-polymerase chain reaction (qRT-PCR) using FastStart Essential DNA Green Master Mix (Roche, Penzberg, Germany) on a Roche LightCycler 480 (Roche, Penzberg, Germany). RNA expression was normalized to GAPDH expression. All quantitative PCRs were conducted in triplicate. Divergent primers, rather than the more commonly used convergent primers, were designed for lncRNAs. We verified the specificity of the PCR primers using BLAST. A single peak in the melt curve indicated that the PCR products were specific.

**Rapid amplification of cDNA ends assay**

Total RNA extracted from preadipocytes was subjected to rapid amplification of cDNA ends (RACE) PCR with the SMARTer RACE 5′/3′ Kit (Clontech, Palo Alto, CA, USA) according to the manufacturer’s specifications.

**Prediction of the relationship between LncRNAs and microRNAs**

DIANA-LncBase v2 was used to predict microRNA binding sites positioned on lncRNAs. DIANA-LncBase was the first extensive database dedicated to cataloging miRNA–lncRNA interactions and contains the largest collection of experimentally supported and in silico predicted miRNA recognition elements (MREs) on lncRNAs. Each miRNA–lncRNA interacting pair was characterized by a cumulative score, which signifies the interaction strength.

**LncRNA knockdown and microRNA overexpression**

Small interfering RNAs (siRNAs) were designed by GenePharma to target LncRNAs (Shanghai, China). Cells were transfected using Lipofectamine 2000 (Invitrogen, CA, USA). After 48 h of siRNA knockdown, lncRNA expression was measured using qRT-PCR. All of the miRNA mimics and inhibitors were synthesized by GeneCopoeia (Rockville, MD, USA).

**LncRNA in vivo precipitation**

Biotin-labeled lncRNA probes were synthesized by GenePharma (Shanghai, China) (Table S2). The lncRNA in vivo precipitation (lncRIP) assay was performed as previously described. Preadipocytes were washed with ice-cold phosphate-buffered saline (PBS), fixed using formaldehyde, lysed in co-IP buffer, and sonicated. After centrifugation, the supernatant was added to a probes–M280 Streptavidin Dynabeads (Invitrogen) mixture and further incubated overnight at 30°C for 12 h. Next, the probes–Dynabeads–lncRNA mixture was washed and incubated with lysis buffer and proteinase K. Finally, TRIzol Reagent (Invitrogen) was added to the mixture for RNA extraction and detection.

**Biotin-coupled miRNA capture**

The biotin-coupled miRNA pull-down assay was performed as previously described. Briefly, 3′-end
biotinylated miR-587 mimics (Ribio, Guangzhou, China) were transfected into preadipocytes for 48 h before harvest. The cell pellets were incubated with lysis buffer on ice. Then, streptavidin-coated magnetic beads (Life Technologies) were added to the cell lysates to pull down the biotin-coupled RNA complex. The abundance of RP11-142A22.4 in the bound fraction was evaluated by qRT-PCR analysis.

RNA immunoprecipitation
RNA immunoprecipitation (RIP) experiments were performed using a Magna RIP RNA-Binding Protein Immunoprecipitation Kit (Millipore, Billerica, MA) according to the manufacturer’s instructions.AGO2 antibody (Cell Signaling Technology, Beverly, MA) was used for RIP. Coprecipitated lncRNAs were detected by qRT-PCR.

Fluorescent in situ hybridization
RNA fluorescence in situ hybridization (RNA-FISH) was performed following the instructions of the probe manufacturer (RiboBio, Guangzhou, China). Preadipocytes were sequentially treated with 70%, 85%, and absolute ethanol and dried at 25 °C. After 0.1% Triton X-100 transmembrane treatment, the cells were incubated with 20 mg/ml RP11-142A22.4 probe overnight at 37 °C. Nuclei were dyed with DAPI. The intracellular localization of RP11-142A22.4 was observed using a TCS SP8 X laser confocal microscope (Leica).

Plasmid constructs
RP11-142A22.4 was amplified from human genomic DNA and cloned into the pCDNA3.1 vector (Geneseed Biotech Co., Guangzhou, China). Mutations in the miRNA binding sites in the lncRNA sequence were introduced using a Fast Site-Directed Mutagenesis Kit (Takara Bio Inc., Dalian, China). All of the constructs were confirmed by sequencing.

Dual-luciferase reporter assay
The wild-type RP11-142A22.4 sequence was cloned into the pmiR-RB-Report vector (RiboBio Co., Guangzhou, China), and mutants were generated using site-directed mutagenesis as described above. The mutations were confirmed by sequencing, with vectors containing a mutant sequence used as a control. Preadipocytes were seeded in 96-well plates at a density of 4 x 10^3 cells per well 24 h before transfection. The cells were then transfected with the wild-type or a mutated reporter vector, and lysates were obtained 24 h post-transfection. The dual-luciferase assay was performed using the Dual-Glo Luciferase Reporter System (Promega, Madison, WI) according to the manufacturer’s protocols.

Western blot analysis
Proteins were extracted from cultured cells and VAT using RIPA lysis buffer. The protein concentration was determined with a bicinchoninic acid protein assay kit (Sigma). Proteins were separated by 12% SDS-PAGE and transferred to PVDF membranes. After blocking for 1 h, the membranes were incubated with primary antibody at 4 °C overnight. The following antibodies were used: anti-Wnt5β (1:000; Abcam, Cambridge, UK), anti-C/EBP-α and anti-PPAR-γ (1:000; Cell Signaling Technology, Danvers, MA, USA). Membranes were incubated with the appropriate HRP-conjugated secondary antibody at room temperature for 2 h. The immunoreactive bands were visualized using ECL and normalized to GAPDH (the internal control).

Preadipocyte isolation and differentiation
Preadipocytes from VAT were isolated and cultured following standard protocols12. In brief, VAT was digested with collagenase to obtain stromal cells. Stromal cells were separated from mature adipocytes by centrifugation and then incubated in erythrocyte lysis buffer for 10 min at room temperature to eliminate red blood cells. The remaining debris was removed by filtering the cell suspension through a 70-μm nylon filter and centrifuging the filtrate. Pelleted preadipocytes were plated in basal medium consisting of DMEM/F-12 (Gibco, Carlsbad, CA) supplemented with 10% fetal calf serum (FCS) and incubated for 16–18 h. After incubation, attached cells were washed thoroughly with warm PBS, removed from plates with trypsin, resuspended, and counted.

We then induced preadipocyte differentiation by incubating cells (at 2 days post-confluence; defined as day 0) in induction medium supplemented with 5 μg/ml insulin (MedChem Express), 1 μM dexamethasone, and 0.5 mM methylisobutylxanthine for 48 h. The induction medium was replaced with DMEM containing 5 μg/ml insulin, and cells were incubated for an additional 48 h. Then, cells were incubated in DMEM containing 10% FBS until most of the cells had differentiated into mature adipocytes with abundant lipid droplets (day 6).

Oil Red O staining
Intracellular lipid deposits were visualized by staining with Oil Red O. At different time points after the medium was changed, wild-type preadipocytes were stained with 30% Oil Red O in isopropanol for 60 min. The lipid deposits in differentiated cells were identified using light microscopy. To quantify the degree of preadipocyte differentiation, spectrophotometric quantification of the stain was performed by dissolving the stained Oil Red O with isopropanol for 5 min. The absorbance of the extract was measured at 540 nm.
Statistical analyses

All statistical analyses were performed with SPSS v20.0 (SPSS Inc., Chicago, IL). Student’s t test was used to compare the two groups. The chi-square test was used to identify significant correlations between RP11-142A22.4 expression and clinical-pathological features in obese patients. Multivariate logistic regression was performed to estimate odds ratios for the potential predictors of 1-year nonremission. P < 0.05 was considered to indicate statistical significance.

Results

Expression profile of lncRNA in VAT

We identified 331 lncRNAs with significantly differential expression in VAT between lean and obese people (P < 0.05). Of these lncRNAs, 153 were upregulated and 178 were downregulated. Unsupervised hierarchical clustering analysis results of the expression of the top 20 differentially expressed lncRNAs are shown in a heat map (Fig. 1a). Significantly differentially expressed lncRNAs were identified using volcano plot filtering (Fig. 1b). Both functional enrichment analysis and KEGG signaling pathway analysis also suggested that the abnormal expression of lncRNAs was associated with lipopolysaccharide syndrome and its related pathway (Fig. 1c, d).

We also constructed a network containing lncRNA-miRNA-mRNA pathways, which might be responsible for the regulation of the biological mechanisms underlying obesity (Supplementary Fig. 1).

Identification and characterization of RP11-142A22.4

After examining the obtained microarray data, we focused on the top 10 differentially expressed lncRNAs (i.e., with the largest fold changes) for further examination (Table S3). These lncRNAs were further examined using qRT-PCR; 10 obese and 10 lean VAT samples were
examined (Fig. 1e). The most significantly differentially expressed lncRNA was RP11-142A22.4, and based on the human reference genome GRCh37/hg19, we found that RP11-142A22.4 (chr4: 145335263-145340421) is located on chromosome 4q31 (Fig. 2a). The sequence of RP11-142A22.4 was confirmed by Sanger sequencing (Supplementary Fig. 2).

To determine both ends of this transcript, we performed 5’ and 3’ RACE assays in preadipocytes (Fig. 2b). We then examined the coding potential of RP11-142A22.4 using NONCODE databases and LncRBase. These data consistently indicated that RP11-142A22.4 had no ability to encode a protein. Moreover, we used a dual-luciferase vector system to test the putative translation ability of RP11-142A22.4. Full-length RP11-142A22.4 sequences were cloned between the RLuc and Luc reporter genes. RLuc and Luc reporters with independent start and stop codons were directly connected in the empty vector (Fig. 2c). As empty vectors, full-length RP11-142A22.4 could not induce Luc activity (Fig. 2d). To assay the subcellular
Fig. 3 RP11-142A22.4 upregulation predicts aggressive clinical-pathological characteristics and regulates preadipocyte differentiation in vitro. a RP11-142A22.4 expression in adipose tissues from 60 obese patients and 40 lean patients. b Pearson correlation between RP11-142A22.4 expression and BMI in the adipose tissues of 60 obese patients. c ROC curve for RP11-142A22.4 that indicates a diagnostic value for this lncRNA in obese patients. d Valuation of RP11-142A22.4 expression after siRNA treatment using qRT-PCR. e, f C/EBP-α and PPAR-γ expression was quantified using qRT-PCR after RP11-142A22.4 knockdown during preadipocytes differentiation. g Oil red O staining of differentiated preadipocytes after transfection with RP11-142A22.4 specific siRNA versus scramble controls. Scale bar = 100 µm. h C/EBP-α and PPAR-γ expression was quantified using western blot assay after RP11-142A22.4 knockdown during preadipocytes differentiation. Data are presented as means ± SD; significant difference was identified with Student’s t test. *P < 0.05; **P < 0.01; ns, not significant.
Table 1  RP11-142A22.4 expression in obese sample.

| Clinical or molecular feature | RP11-142A22.4 (30) over-expression | RP11-142A22.4 (30) down-expression | P     |
|------------------------------|-------------------------------------|-------------------------------------|-------|
| Age (y)                      | 25 ± 3.74                           | 30.9 ± 5.6                          |       |
| Gender (M/F)                 | 7/23                                | 7/23                                | —     |
| BMI (kg/m²)                  | 41.1 ± 6.3                          | 35.3 ± 4.4                          | 0.001 |
| Systolic BP (mm Hg)          | 127.6 ± 10.9                        | 132.0 ± 17.5                        | 0.256 |
| Diastolic BP (mm Hg)         | 78.1 ± 7.4                          | 84.5 ± 12.7                         | 0.022 |
| Diabetes                     | 13.3% (4/30)                        | 16.6% (5/30)                        | 0.723 |
| Hyperuricemia (HUA)          | 26.7% (8/30)                        | 13.3% (4/30)                        | 0.203 |
| Hyperlipemia (HLP)           | 53.3% (16/30)                       | 63.3% (19/30)                       | 0.441 |
| Obstructive sleep apnea (OSAS)| 76.6% (23/30)                       | 53.3% (16/30)                       | 0.060 |
| Hyperinsulinemia (HINS)      | 6.6% (2/30)                         | 16.6% (5/30)                        | 0.235 |

Italic value stands for specific p values.

distribution of RP11-142A22.4, we performed RNA-FISH and qRT-PCR. Our results show that most of the RP11-142A22.4 transcripts were located in the cytoplasm (Fig. 2e, f and Supplementary Fig. 3).

RP11-142A22.4 upregulation predicts aggressive clinical-pathological characteristics

As RP11-142A22.4 expression was significantly increased in VATs from obese patients, we next analyzed whether RP11-142A22.4 upregulation was correlated with the prognosis of these patients. We used qRT-PCR to quantify RP11-142A22.4 expression in a cohort of 60 obese patients for whom prognostic data were available. RP11-142A22.4 expression was significantly upregulated in the VATs from obese patients compared to the VATs from lean patients (Fig. 3a). We also analyzed the association between RP11-142A22.4 expression and the clinical-pathological status of obese patients. RP11-142A22.4 expression was positively correlated with body mass index (BMI) (P < 0.01) in obese patients (Fig. 3b and Table 1). Furthermore, ROC analysis was performed with an RP11-142A22.4 cut-off ≥ 2.298 and showed a high diagnostic performance, as reflected by the Youden index (sensitivity, 90.0%; specificity, 96.7%; Fig. 3c).

RP11-142A22.4 regulates preadipocyte differentiation in vitro

To explore the role of RP11-142A22.4 in preadipocytes, we successfully knocked down RP11-142A22.4 in preadipocytes from obese patients (Fig. 3d). Oil Red O staining indicated that RP11-142A22.4 knockdown downregulated preadipocyte differentiation (Fig. 3g).

The expression levels of C/EBP-α and PPAR-γ, which are biomarkers of preadipocyte differentiation, were decreased in RP11-142A22.4 knockdown cells, as quantified by qRT-PCR and western blot analysis (Fig. 3e, f, h and Supplementary Fig. 4). Similar results were obtained using preadipocyte from the subcutaneous adipose tissue (SAT) samples of obese patients (Supplementary Fig. 5).

RP11-142A22.4 might function as a sponge for miR-587

In addition to epigenetic regulation in the nucleus, lncRNAs can regulate target gene expression by functioning as competing endogenous RNAs (ceRNAs) for specific miRNAs in the cytoplasm. RP11-142A22.4 was identified as a cytoplasm-enriched abundant lncRNA in preadipocytes. The potential targets of RP11-142A22.4 were predicted using a bioinformatics database (DIANA-LncBase v2). Using this approach, we identified 10 potential interacting miRNAs and constructed an RP11-142A22.4–miRNA–mRNA network (Supplementary Fig. 1 and Table S4).

To further explore RP11-142A22.4 associations, a lncRIP assay with antibodies against Argonaute 2 (AGO2) was chosen because AGO2 plays an important role in mRNA-induced RNA silencing. The results show that the anti-AGO2 antibody significantly enriched RP11-142A22.4 (Fig. 4a), suggesting that RP11-142A22.4 acts as a binding platform for AGO2 and miRNAs. Additionally, RP11-142A22.4-associated miRNAs were purified by lncRIP with specific probes targeting RP11-142A22.4. The results show that RP11-142A22.4 and miR-587 were both enriched in the examined preadipocytes (Fig. 4b and Supplementary Fig. 6). This association was further confirmed using RNA-FISH, which showed that RP11-142A22.4 and miR-587 are colocalized in preadipocytes (Fig. 4c).

To examine the predicted RP11-142A22.4 binding sites (Fig. 4d), a dual-luciferase assay was performed. The results show that high binding affinity exists between RP11-142A22.4 and miR-587 (Fig. 4e). Furthermore, miR-587 reduced luciferase reporter activity by >50% compared to the control (Fig. 4e). After mutating the miR-587 target sites in the luciferase reporter, no significant change in luciferase activity was observed following transfection with miR-587 and the luciferase reporter (Fig. 4f). Furthermore, a pull-down assay using biotin-coupled miR-587 showed obvious enrichment of RP11-142A22.4 compared with the controls (Fig. 4g).

To verify whether RP11-142A22.4 regulates the expression of miR-587, miR-587 expression was examined following RP11-142A22.4 overexpression or knockdown in preadipocytes. After knockdown of RP11-142A22.4, the expression of miR-587 was significantly upregulated (Fig. 4b). We also found a significant negative correlation between RP11-142A22.4 and miR-587 expression in VAT
Thus, our results suggest that RP11-142A22.4 knockdown suppresses preadipocyte differentiation by reducing the functionality of miR-587.

Knockdown of RP11-142A22.4 inhibits preadipocyte differentiation via the miR-587/Wnt5β pathway

The bioinformatics method TargetScan predicted that Wnt5β is a possible downstream gene of miR-587 (Supplementary Fig. 7). Thus, we hypothesized that RP11-142A22.4 induces preadipocyte differentiation by protecting the differentiation promoting factor Wnt5β from downregulation by miR-587. To test this hypothesis, we overexpressed miR-587 mimics and measured the expression of their respective targets via qRT-PCR (Table S2). Following mimic transfection into preadipocytes, Wnt5β was found to exhibit a significant decrease in gene expression (Fig. 5a). Furthermore, RP11-142A22.4 knockdown significantly reduced Wnt5β expression.

(Fig. 4i). Thus, our results suggest that RP11-142A22.4 knockdown suppresses preadipocyte differentiation by reducing the functionality of miR-587.
RP11-142A22.4 overexpression or miR-587 inhibition increased Wnt5β expression (Fig. 5c, d).

To further examine Wnt5β, the 3′ untranslated region (UTR) of Wnt5β was cloned into a luciferase vector, and the effect of miR-587 in the presence or absence of RP11-142A22.4 was examined. Our data showed that no significant change in luciferase activity was observed following transfection with RP11-142A22.4 compared with the control (Supplementary Fig. 8). In preadipocytes overexpressing miR-587, the luciferase reporter activity was enhanced in those containing the wild-type Wnt5β (Wnt5β-wt) (e) or a Wnt5β construct with mutated miR-587 binding sites (Wnt5β-mut) (f). g, h. Reversion assays using vectors overexpressing or knocking down RP11-142A22.4, as well as miR-587 mimics or inhibitors. Data are presented as means ± SD; significant difference was identified with Student’s t test. *P < 0.05; **P < 0.01; ns, not significant.

Discussion

LncRNAs are emerging as an important new class of regulators that impact diverse biological processes and the pathogenesis of obesity. Recent studies have confirmed the relationship between obesity and dysregulation
of adipogenesis. Some lncRNAs have been found to be associated with preadipocyte differentiation and adipogenesis, and the altered expression of lncRNAs was correlated with the occurrence and development of obesity. IncOb can control leptin expression by interacting with its proximal promoter. Additionally, mice with diet-induced obesity with IncOb knockout exhibit increased fat mass, with reduced plasma leptin levels. Through interaction with hnRNPU and IGF2BP2 at distinct subcellular locations, linc-ADAL regulates adipocyte differentiation and lipogenesis. Lnc-U90926 attenuates preadipocyte differentiation by inhibiting the transactivation of PPAR-γ. In the present study, we found a novel regulator of preadipocyte differentiation, RP11-142A22.4, which is upregulated in the VAT of obese patients and predicts negative outcomes. Furthermore, RP11-142A22.4 promotes preadipocyte differentiation and acts as a ceRNA by sponging miR-587 to modulate Wnt5β expression.

LncRNAs have been reported to be located in both the nucleus and the cytoplasm, and subcellular localization patterns of lncRNAs reveal fundamental insights into their biology and provide hypotheses for potential molecular roles. Recently, a novel mechanism of post-transcriptional regulation has been identified, i.e., that lncRNAs function as a natural miRNA sponge, interfere with miRNA pathways, and regulate the derepression of miRNA targets. The miRNA sponge function of RP11-142A22.4 is consistent with the evidence from our study. First, using a coding potential calculator and a coding potential assessment tool, it is suggested that lncRNAs have very poor protein-coding potential. Second, RP11-142A22.4 was predominantly located in the cytoplasm and negatively correlated with miR-587 in the VAT of obese patients. Third, the interaction between RP11-142A22.4 and miR-587 was predicted using a bioinformatics database, which predicted that RP11-142A22.4 contains a miR-587 binding site. Fourth, miR-587 downregulation efficiently reversed the inhibition of differentiation by RP11-142A22.4 siRNA. Moreover, miR-587 upregulation significantly reduced differentiation in the presence of RP11-142A22.4. Finally, we found that RP11-142A22.4 could pull down miR-587; in fact, the highest binding affinity occurred between RP11-142A22.4 and miR-587. In addition to interaction with miRNAs, a single lncRNA could play additional roles in the cytoplasm, including in the regulation of different mechanisms.

A previous report demonstrated that the expression of PPAR-γ and C/EBP-α was increased in Wnt5β-overexpressing differentiated cells. Wnt5β is able to promote adipogenesis in 3T3-L1 cells by inhibiting the canonical Wnt/β-catenin pathway. In this study,
using a bioinformatics database, miR-587 was predicted to target the 3'UTR of Wnt5β, which was confirmed using a dual-luciferase assay in preadipocytes. A previous study demonstrated that miR-587 could target the 3'UTR of PPP2R1B in colorectal cancer. Our data show that miR-587 targets Wnt5β more obviously than PPP2R1B in preadipocytes (Supplementary Fig. 11). Moreover, our findings indicate that lncRNAs can target miR-587 and subsequently promote Wnt5β and downstream PPAR-γ and C/EBP-α expression in preadipocytes. In addition, Wnt5β mRNA expression was relatively high in adipocytes obtained from obese patients who exhibited increased lncRNA expression. Therefore, these findings provide evidence for the notion that post-transcriptional regulation of Wnt5β by lncRNA depends on miR-587 in preadipocytes. However, RP11-142A22.4 is not conserved over, in our study, both GO analysis and KEGG analysis also showed the important role of the differentially expressed lncRNAs identified through microarray analysis in the inflammatory response of adipocytes. Additionally, our lncRNA-miRNA-mRNA network indicated that lncRNAs may target inflammation-related miRNAs and mRNAs. However, further research is needed to understand the effect of lncRNAs on obesity-related inflammation.

In summary, we identified RP11-142A22.4 as an important factor associated with obesity, which plays a key role in adipocyte differentiation and adipogenesis. Moreover, we report the interaction between RP11-142A22.4 and miR-587 for the first time, and we reveal that RP11-142A22.4 regulates the expression of Wnt5β by sponging miR-587 in preadipocytes. Our results provide a foundation for further functional, diagnostic, and therapeutic studies related to RP11-142A22.4 in obese patients.

Acknowledgements
This work was supported by grants from the National Natural Science Foundation of China (81502075) and the Foundation of Science and Technology of Sichuan Province (2019YJ0635). The funders had no role in study design and implementation.

Author details
1Medical Research Center, The Third People's Hospital of Chengdu, The Second Affiliated Hospital of Chengdu, Chongqing Medical University, Chengdu 610031 Sichuan Province, China. 2Affiliated Hospital of Southwest Jiaotong University, Chengdu 610036, China. 3Center for Obesity and Metabolic Diseases, The Third People's Hospital of Chengdu, The Second Affiliated Hospital of Chengdu, Chongqing Medical University, Chengdu 610031 Sichuan Province, China. 4Department of Outpatient, The Third People's Hospital of Chengdu, The Second Affiliated Hospital of Chengdu, Chongqing Medical University, Chengdu 610031 Sichuan Province, China

Data availability
LncRNA microarray datasets obtained from gene expression analyses in this study have been deposited to the NCBI GEO repository and are available through accession code GSE131819. Other relevant data supporting the findings of this study are available within the article and supplementary files or from the authors upon reasonable request.

Conflict of interest
The authors declare that they have no conflict of interest.

Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information accompanies this paper at (https://doi.org/10.1038/s41419-020-2550-9).

Received: 16 December 2019 Revised: 21 April 2020 Accepted: 22 April 2020
Published online: 19 June 2020

References
1. Lafort, S., Labrecque, J., Michaud, A., Ciarlone, K. & Tchernoif, A. Adipocyte size as a determinant of metabolic disease and adipose tissue dysfunction. Crit. Rev. Clin. Lab. Sci. 52, 301–313 (2015).
2. Marcelin, G. & Clément, K. Adipose tissue fibrosis: an aggravating factor in obesity. Med Sci. (Paris) 34, 424–431 (2018).
3. Yang, W., Kelly, T. & He, J. Genetic epidemiology of obesity. Epidemiol. Rev. 29, 49–61 (2007).
4. Batista, P. J. & Chang, H. Y. Long noncoding RNAs: cellular address codes in development and disease. Cell 152, 1298–1307 (2013).
5. Adams, B. D., Parsons, C., Walker, L., Zhang, W. C. & Slack, F. J. Targeting noncoding RNAs in disease. J. Clin. Invest. 127, 761–771 (2017).
6. Ponting, C. P., Oliver, P. L. & Reik, W. Evolution and functions of long non-coding RNAs. Cell 136, 629–641 (2009).
7. Chen, Z. Progress and prospects of long non-coding RNAs in lipid homeostasis. Mol. Metab. 5, 164–170 (2016).
8. Divoux, A. et al. Identification of a novel lncRNA in gluteal adipose tissue and evidence for its positive effect on preadipocyte differentiation. Obes. (Silver Spring) 22, 1781–1785 (2014).
9. Paraskevopoulos, M. D. et al. DIANA-LncBase v2: indexing microRNA targets on non-coding transcripts. Nucleic Acids Res. 44, D231–238 (2016).
10. Wu, X. S. et al. LncRNA-PAGBC acts as a microRNA sponge and promotes gallbladder tumorigenesis. EMBO Rep. 18, 1837–1853 (2017).
11. Lai, A. et al. Capture of microRNA-bound mRNAs identifies the tumor suppressor miR-34a as a regulator of growth factor signaling. PLoS Genet. 7, e1002363 (2011).
12. Divoux, A. et al. MicroRNA-106 Regulates HOX Gene Expression in Human Guteal Adipose Tissue. Obes. (Silver Spring) 25, 1375–1383 (2017).
13. Prusty, D., Park, B. H., Davis, K. E. & Farmer, S. R. Activation of MEK/ERK signaling promotes adipogenesis by enhancing peroxisome proliferator-activated receptor gamma (PPARgamma) and C/EBPalpha gene expression during the differentiation of 3T3-L1 preadipocytes. J. Biol. Chem. 277, 46226–46232 (2002).
14. Zuo, Y., Qiang, L. & Farmer, S. R. Activation of CCAAT/enhancer-binding protein (C/EBP) alpha expression by C/EBP beta during adipogenesis requires a peroxisome proliferator-activated receptor-gamma-associated repression of HDAC1 at the C/EBP alpha gene promoter. J. Biol. Chem. 281, 7960–7967 (2006).
15. Fatica, A. & Bozzoni, I. Long non-coding RNAs: new players in cell differentiation and development. Nat. Rev. Genet. 17, 7–21 (2016).
16. Liu, J. et al. Argonaute2 is the catalytic engine of mammalian RNAi. Science 305, 1437–1441 (2004).
17. Kanazawa, A. et al. Association of the gene encoding wingless-type mammary tumor virus integration-site family member 5B (WNT5B) with type 2 diabetes. Am. J. Hum. Genet. 75, 832–843 (2004).
18. van Tienen, F. H., Laeremans, H., van der Kallen, C. J. & Smeets, H. J. Wnt5b stimulates adipogenesis by activating PPARgamma, and inhibiting the beta-catenin dependent Wnt signaling pathway together with Wnt5a. Biochem. Biophys. Res. Commun. 387, 207–211 (2009).
19. Sun, L. et al. Long noncoding RNAs regulate adipogenesis. Proc. Natl Acad. Sci. USA 110, 3387–3392 (2013).
20. Alvarez-Dominguez, J. R. et al. De novo reconstruction of adipose tissue transcriptomes reveals long non-coding RNA regulators of brown adipocyte development. Cell Metab. 21, 764–776 (2015).
21. Rosen, E. D. & MacDougal, O. A. Adipocyte differentiation from the inside out. Nat. Rev. Mol. Cell Biol. 7, 885–896 (2006).
22. Wang, Y. et al. Long non-coding RNA CASC2 suppresses epithelial-mesenchymal transition of hepatocellular carcinoma cells through CASC2/miR-367/FBXW7 axis. Mol. Cancer 16, 123 (2017).
23. Dallner, O. S. et al. Dysregulation of a long noncoding RNA reduces leptin leading to a leptin-responsive form of obesity. Nat. Med. 25, 507–516 (2019).
24. Zhang, X. et al. Interrogation of nonconserved human adipose lincRNAs identifies a regulatory role of linc-ADAL in adipocyte metabolism. Sci. Transl. Med. 10, eaar5987 (2018).
25. Chen, J. et al. The role and possible mechanism of IncRNA U90926 in modulating 3T3-L1 preadipocyte differentiation. Int J. Obes. (Lond.) 41, 299–308 (2017).
26. Derrien, T. et al. The GENCODE v7 catalog of human long noncoding RNAs: analysis of their gene structure, evolution, and expression. Genome Res 22, 1775–1789 (2012).
27. van Heesch, S. et al. Extensive localization of long noncoding RNAs to the cytosol and mono- and polyribosomal complexes. Genome Biol. 15, R6 (2014).
28. Salmena, L., Poliseno, L., Tay, Y., Kats, L. & Pandolfi, P. P. A ceRNA hypothesis: the Rosetta Stone of a hidden RNA language. Cell 146, 353–358 (2011).
29. Kanazawa, A. et al. Wnt5b partially inhibits canonical Wnt/beta-catenin signaling pathway and promotes adipogenesis in 3T3-L1 preadipocytes. Biochem. Biophys. Res. Commun. 330, 498–505 (2005).
30. Zhang, Y., Talmon, G. & Wang, J. MicroRNA-587 antagonizes 5-FU-induced apoptosis and confers drug resistance by regulating PPP2R1B expression in colorectal cancer. Cell Death Dis. 6, e1845 (2015).